

## Questions for Vancomycin

What are your clinical experiences with vancomycin dosing, and have you noticed any differences in patient outcomes between continuous and intermittent regimens?

Based on the current literature, what factors do you consider most important when deciding between continuous and intermittent dosing for patients with renal impairment?

How do you incorporate pharmacokinetic and pharmacodynamic data into your clinical decision-making process regarding vancomycin dosing?

What criteria do you use to determine whether to prescribe continuous or intermittent dosing of vancomycin in your patients?

How do you think renal impairment influences your decision-making regarding vancomycin dosing strategies?

What challenges have you faced in applying pharmacokinetic and pharmacodynamic principles to your vancomycin prescribing practices?